Her primary scientific interests are in Multiple myeloma, Internal medicine, Surgery, Thalidomide and Bortezomib. Her research in Multiple myeloma intersects with topics in Radiology, Dexamethasone and Pharmacology. Her work in Internal medicine covers topics such as Oncology which are related to areas like Refractory and Stem cell.
Her studies deal with areas such as Adverse effect and Cause of death as well as Surgery. Her Thalidomide research includes elements of Randomized controlled trial and Urology. Her Bortezomib research is multidisciplinary, incorporating perspectives in Proteasome inhibitor, Cancer research, Standard treatment, Leukemia and Autologous transplantation.
Internal medicine, Multiple myeloma, Oncology, Bortezomib and Thalidomide are her primary areas of study. The various areas that Sonja Zweegman examines in her Internal medicine study include Gastroenterology and Surgery. Her Multiple myeloma study incorporates themes from Newly diagnosed, Dexamethasone and Cancer research.
Sonja Zweegman has researched Bortezomib in several fields, including Proteasome inhibitor, Proteasome and Pharmacology. Her Thalidomide research incorporates themes from Regimen, Randomized controlled trial, Maintenance therapy and Prednisone. Her biological study spans a wide range of topics, including Adverse effect, Progression-free survival and Clinical trial, Phases of clinical research.
Her primary areas of investigation include Multiple myeloma, Internal medicine, Oncology, Daratumumab and Cancer research. Her Multiple myeloma research includes themes of Clinical trial, Intensive care medicine and Immunotherapy. Her study involves Newly diagnosed, Dexamethasone, Transplantation, Myelofibrosis and Thalidomide, a branch of Internal medicine.
Her work in the fields of Oncology, such as Autologous stem-cell transplantation, intersects with other areas such as In patient. She has included themes like Antibody, CD38, Cytotoxic T cell, Chimeric antigen receptor and Bone marrow in her Cancer research study. Sonja Zweegman focuses mostly in the field of Lenalidomide, narrowing it down to matters related to Maintenance therapy and, in some cases, Placebo.
Her primary scientific interests are in Multiple myeloma, Internal medicine, Daratumumab, Transplantation and Oncology. Her Multiple myeloma research is multidisciplinary, relying on both Disease and Intensive care medicine. Sonja Zweegman works mostly in the field of Daratumumab, limiting it down to topics relating to Cancer research and, in certain cases, Immunotherapy, Ex vivo, Bone marrow and Chimeric antigen receptor.
She combines subjects such as Ixazomib, Systematic review and Radiology with her study of Transplantation. Her research integrates issues of Meta-analysis, Hematopoietic stem cell transplantation and Hazard ratio, Confidence interval in her study of Oncology. Her Thalidomide study combines topics from a wide range of disciplines, such as Median follow-up and Standard treatment.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari.
Journal of Clinical Oncology (2012)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos.
Annals of Oncology (2010)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau;Michel Attal;Cyrille Hulin;Bertrand Arnulf.
The Lancet (2019)
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca.
The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells
Anna Van Rhenen;Guus A.M.S. Van Dongen;Angè Le Kelder;Elwin J. Rombouts.
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
Anna van Rhenen;Nicole Feller;Angèle Kelder;August H. Westra.
Clinical Cancer Research (2005)
Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)
Antonio Palumbo;Sara Bringhen;Heinz Ludwig;Meletios A. Dimopoulos.
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Robyn M. Emanuel;Amylou C. Dueck;Holly L. Geyer;Jean Jacques Kiladjian.
Journal of Clinical Oncology (2012)
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
Henk M. Lokhorst;Bronno van der Holt;Sonja Zweegman;Edo Vellenga.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: